"Orange Book" Patent Abuses Could Be Addressed By FDA Limitations - Atty.
This article was originally published in The Tan Sheet
Executive Summary
FDA should issue regulations limiting "Orange Book" patent listings by brand name pharmaceutical companies to those patents that claim the listed drug or approved method of use, attorney David Weeda suggested at the Warburg Dillon Read Specialty Pharmaceutical Conference in New York City May 26. Weeda, a partner at the D.C. firm Olsson, Frank and Weeda, is a former FDA associate chief counsel.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: